Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Post by WalkOverTheStrton Aug 30, 2023 9:24am
97 Views
Post# 35611606

Correcting GrahamB's inaccurate statement

Correcting GrahamB's inaccurate statement Graham

They have made this warning before (see below) so not sure why you are stating they haven't made this statement before... 

VENTRIPOINT DIAGNOSTICS LTD. Management’s Discussion & Analysis – Quarterly Highlights Three Months Ended March 31, 2023 Dated May 30, 2023

https://www.ventripoint.com/_files/ugd/8e5203_6163d327e7974cdcb5a6eff9495cb751.pdf

As a result, there is a material uncertainty which creates significant doubt regarding the Company's ability to continue as a going concern

There is no certainty whether the Company will generate significant revenues or attain profitable operations in the near future and there can be no assurance that it will achieve profitability in the future, as it incurred a loss of $3,768,472 and had a negative cash flow from operating activities of $3,091,712 for the nine months ended March 31, 2023, and has accumulated $47,516,684 of losses as at March 31, 2023 (December 31, 2021 - accumulated losses of $43,748,212). As a result, there is a material uncertainty which creates significant doubt regarding the Company's ability to continue as a going concern
<< Previous
Bullboard Posts
Next >>